News | May 25, 2021
Orchid Pharma to transfer IKKT undertaking to JV with Bionpharma
The turnover of its NPNC Formulations Division (IKKT Undertaking) for FY 2020-2021 is Rs.21.33 Cr
The turnover of its NPNC Formulations Division (IKKT Undertaking) for FY 2020-2021 is Rs.21.33 Cr
The antibody cocktail is to be administered for the treatment of mild to moderate COVID-19
BALflu is approved by DCGI for emergency use for the treatment of COVID-19
Posaconazole is a triazole antifungal agent indicated for treating mucormycosis patients
The company has reported total income of Rs.826.40 crores for FY 2020-21
It posted net profit of Rs.188.77 crores for the period ended March 31, 2020.
The company plans to enter the EU markets in FY22
Allecra Therapeutics would now either directly or through out license file for NDA of this molecule.
We focused on developing the product last year but now our focus is on ramping up our manufacturing capacity
The company reported total income of Rs.455.28 crores during the 12 months period ended March 31, 2021
Subscribe To Our Newsletter & Stay Updated
